The intercalative acridine derivative 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA), but not its isomer o-AMSA, is a potent antitumor drug that in mammalian cells stimulates the formation of DNA strand breaks that are characterized by tightly bound proteins. Using purified mammalian DNA topoisomerases, we have analyzed the effects of these antitumor drugs on topoisomerase-DNA interactions. The antitumor drug m-AMSA dramatically stimulates the formation of a topoisomerase II-DNA complex that is detected on protein-denaturant treatment: both single-and double-stranded DNA breaks are produced and a topoisomerase II subunit is linked covalently to each 5' end of the broken DNA strands. The noncytotoxic isomer, o-AMSA, which does not induce significant amounts of DNA breaks in cultured cells, exhibits a correspondingly smaller effect in stimulating formation of the complex in vitro. The agreement between in vitro and in vivo studies suggests that mammalian DNA topoisomerase II may be the primary target of m-AMSA and that the drug-induced complex formation between topoisomerase II and DNA may be the cause of cytotoxicity and other effects such as DNA sequence rearrangements and sister-chromatid exchange.
double-stranded DNA breaks are produced and a topoisomerase II subunit is linked covalently to each 5' end of the broken DNA strands. The noncytotoxic isomer, o-AMSA, which does not induce significant amounts of DNA breaks in cultured cells, exhibits a correspondingly smaller effect in stimulating formation of the complex in vitro. The agreement between in vitro and in vivo studies suggests that mammalian DNA topoisomerase II may be the primary target of m-AMSA and that the drug-induced complex formation between topoisomerase II and DNA may be the cause of cytotoxicity and other effects such as DNA sequence rearrangements and sister-chromatid exchange.
A large number of antitumor drugs are known to interact with DNA in vitro (for review, see ref. 1) . Despite their success in treating certain tumors, the cellular mechanisms of the actions of these drugs are still unknown (1) . Among these antitumor drugs, many of them interact with DNA by an intercalative mode (1) . A cellular phenomenon has been noted that seems to be unique to these intercalative antitumor drugs. After treatment of mammalian cells with these antitumor drugs [e.g., daunomycin, adriamycin, ellipticine, actinomycin D, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA)], DNA breakage can be demonstrated by several techniques (2) (3) (4) (5) (6) (7) . Both single-and double-strand breaks have been observed and their ratio varies depending on the particular drug used. Usually, DNA cleavage is quickly reversed on removal of the drug. The cleavage products have protein tightly (perhaps covalently) associated with the broken DNA ends (2-7). The synthetic antitumor drug m-AMSA, being a weak DNA intercalator (1) , is particularly interesting because similar DNA strand breaks can be shown to occur in both cultured mammalian cells and isolated nuclei (6, (8) (9) (10) (11) (12) . Furthermore, it has been shown that the 5' ends of the cleavage product formed by m-AMSA treatment are blocked by proteins (13) . The suggestion that a DNA topoisomerase may be involved has been made (3, 5, 6, 13) .
Recently, it was shown that a tight complex is formed between purified eukaryotic DNA topoisomerase II and DNA (14, 15) . Mammalian DNA topoisomerase II and DNA can form a tight complex that, on protein-denaturant treatment, produces protein-linked DNA breaks (15) . This complex (henceforth referred to as the "cleavable complex") is operationally defined by the detection method used. One of its unusual features is its reversibility with respect to low-temperature and high-salt treatment (15) . The DNA product after low-temperature or high-salt treatment is identical to the original DNA with respect to its circularity and linking' number (15) . It is likely that the putatively broken DNA (staggered by four bases with each 5' protruding end covalently linked to the enzyme monomer) (14, 15) is fully protected by the bound enzyme so that relative rotation of the two broken ends is inhibited. Many properties of this complex suggested to us that mammalian DNA topoisomerase II may be involved in the action of these intercalative antitumor drugs. In this communication, we report our initial studies indicating that mammalian DNA topoisomerase II may be the primary target for at least one intercalative antitumor drug, m-AMSA.
MATERIALS AND METHODS
Materials. Homogeneous preparations of DNA topoisomerase I and II from both calf thymus and HeLa cells were used (unpublished results). Drosophila DNA topoisomerase II and Escherichia coli gyrase were gifts from T. S. HIsieh and Martin Gellert, respectively. m-AMSA (NSC 249992) and its isomer o-AMSA (NSC 156306) were obtained from the Drug Synthesis and Chemistry Branch, Division of Cancer Treatment, National Cancer Institute. Both drugs were dissolved in dimethyl sulfoxide at 2 mg/ml and used fresh.
Topoisomerase Assays and DNA-Strand Cleavage Conditions. Type II DNA topoisomerase activity was assayed using the P4 unknotting assay described previously (16 4 '-(9-acridinylamino)methanesulfon-m-anisidide and -o-anisidide, respectively.
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by two cycles of ethanol precipitation in the presence of 2 M ammonium acetate (17) .
Quantitative Precipitation of the Covalent Enzyme-DNA Complex. The precipitation method was essentially that described previously (15) . Briefly, reaction mixtures (50 Al each) containing 50 ng of calf thymus DNA topoisomerase II, 25 ng of 3'-end-or 5'-end-labeled pBR322 DNA, and various concentrations of drugs were incubated at 370C for 30 min. The reactions were then terminated by the addition of 100 Al of a prewarmed (370C) solution of 0.2 M NaOH/2% NaDodSO4/5 mM EDTA containing salmon sperm DNA (0.5 mg/ml; Sigma), and this mixture was incubated at 370C for 10 min. Then, the covalent enzyme-DNA complexes (DNA was single-stranded because of alkali denaturation) were precipitated by the addition of 50 ,ul of 0.25 M KCl/0.4 M HCl/0.4 M Tris, pH 7.9. Precipitation was allowed to occur at 0C for 10 min. The precipitate was collected by centrifugation in an Eppendorf centrifuge for 15 min at 40C and washed once by heating to 650C for 10 min in 200 Al of 10 mM Tris-HCl, pH 7.9/100 mM KCl/1 mM EDTA containing carrier DNA at 100 ,ug/ml and bovine serum albumin at 50 ,g/ml. After cooling on ice and recentrifugation, the pellet was suspended in 200 Al of H20, dissolved by heating to 65°C, and transferred to a vial containing 4 ml of scintillation fluid for determination of radioactivity.
Gel Electrophoresis. To demonstrate the presence of the covalent enzyme-DNA complex in the native gel, 0.1% NaDodSO4 was included in the Tris/borate/EDTA (TBE) electrophoresis buffer (17) . Alkaline agarose gel electrophoresis was carried out as described (17) .
RESULTS
The Antitumor Drug m-AMSA Stimulates Formation of the Cleavable Complex. A number of antitumor drugs were tested, using purified mammalian DNA topoisomerase II, for their ability to stimulate DNA cleavage in vitro. m-AMSA was one of the more potent drugs that stimulated formation of the cleavable complex. Its isomer o-AMSA ( Fig. 1) , which is dramatically less potent in both cytotoxic effect on tumor cells and induction of protein-linked DNA breaks in vivo (6, 18) , was also much less potent in stimulating the cleavable complex formation in vitro. 20 ,ug/ml). Lanes B, E, and H, 12 ng/ml; lanes C, F, and I, 60 ng/ml; lanes D, G, and J, 300 ng/ml. Lane A was a DNA control (no enzyme).
all the cleavage products were associated with tightly bound topoisomerase, we compared the gel mobilities of the bands with and without protease treatment (15 Topoisomerase Is Linked to the 5' Termini of Cleaved DNA. To confirm that the m-AMSA-induced cleavable complex is structurally the same as the cleavable complex identified previously in the absence of the drug (15), we analyzed the cleavage products with and without protease treatment on an alkaline agarose gel (Fig. 3) (Fig. 4 , lanes E-G) and m-AMSA (lanes H-J). Both tion, gene expression, and recombination. Its catalytic function is to generate DNA superhelical tension, which has been found both in vivo and in vitro (reviewed in refs. 21 and 22) . Whether eukaryotic DNA topoisomerase II is a true DNA gyrase in vivo remains to be elucidated. Despite this uncertainty, it is likely that eukaryotic DNA topoisomerase II has similar biological functions.
The effect of m-AMSA on eukaryotic DNA topoisomerase II is reminiscent of the effect of oxolinic acid (or nalidixic acid) on bacterial DNA topoisomerase II (21, 22) . In the presence of oxolinic acid, DNA gyrase forms a complex with DNA, which can be activated by treatment with NaDodSO4 to produce double-strand breaks in DNA. Detailed analyses of the broken complex have revealed that the break is a fourbase stagger and that a gyrA subunit is covalently linked to each 5' protruding end of the break (21, 22) . The formation of this complex in vivo in the presence of oxolinic acid presumably poisons DNA gyrase on the DNA template and thus inhibits cell growth (21, 22, 26) . The stimulation of mammalian DNA topoisomerase II to form a similar complex by m-AMSA treatment and the cytotoxic effect of m-AMSA probably represent a eukaryotic analog of this bactericidal effect of oxolinic acid. Based on current knowledge about the topoisomerase-DNA complex, a simple model for the mammalian DNA topoisomerase II-DNA interaction is presented in Fig. 5 . In this model, only the initial steps of the strand-passing mechanism are considered. The ATPase-mediated strand-crossing event that presumably follows these initial steps is not illustrated for reasons of simplicity. Based on the present methods of detection, we assume that at least two forms of topoisomerase-DNA complexes exist that are at equilibrium. The cleavable complex (Fig. 5C ) refers to the complex described above that can be detected by treatment with protein denaturants such as NaDodSO4 or alkali. Mammalian DNA topoisomerase II is most likely a homodimer (Mr, 120,000-170,000) (14, 27) . On protein-denaturant treatment, the cleavable complex falls apart in such a manner that one topoisomerase subunit is covalently linked through a tyrosine residue to each 5' phosphoryl end of the double-strand break (unpublished results). The double-strand break is staggered by four bases with protruding 5' ends (15) . The "noncleavable complex" (Fig. SB) refers to the complex in which the interaction between mammalian DNA topoisomerase II and DNA is noncovalent. Treatment of the noncleavable complex with protein denaturants leads to dissociation of the topoisomerase from DNA. Normally, the equilibrium favors formation of the noncleavable complex and only a very small fraction of the topoisomerase can be trapped as the cleavage product by protein-denaturant treatment. The antitumor drug m-AMSA may alter this equilibrium by acting as an allosteric effector or by forming a topoisomerase-AMSA-DNA ternary complex. In either case, the equilibrium is shifted toward the cleavable complex in the presence of m-AMSA. This model can explain the reversibility of the drug action and the effects of temperature and salt on the cleavable complex (7, (9) (10) (11) (12) 15) .
It is attractive to hypothesize that, similar to oxolinic acid (26) , m-AMSA may alter the state of the cleavable complex such that it may have a higher probability of falling apart in vivo either spontaneously or because some other interaction such as a fast moving replication fork, helicases in motion, or other nuclear proteins. This type of double-strand break, in which one native protein subunit is tightly associated with each end, may abort DNA replication and thus cause cytotoxicity or DNA rearrangement and sister-chromatid exchange (28) . It is conceivable that the alteration of the cleavable complex by m-AMSA may also result in inhibition of the ATP-dependent strand-passing function of topoisomerase II. Indeed, m-AMSA is reproducibly a stronger inhibitor of the strand-passing activity of mammalian DNA topoisomerase II than o-AMSA (Fig. 4) . However, since both drugs are DNA intercalators, we do not know whether this inhibition is a direct result of the altered cleavable complex or drug intercalation into DNA. It is interesting that the ATP-dependent strand-passing activity of type II DNA topoisomerases are sensitive to DNA intercalators (unpublished results). The cytokinetic effect of m-AMSA is a block in the G2 phase of the cell cycle (29) . This block may be related to drug inhibition of the strand-passing activity of DNA topoisomerase II. However, we think that the activity inhibition is not related to the cell killing action of the antitumor drug.
How does m-AMSA alter the cleavable complex formed between DNA topoisomerase II and DNA? Clearly, the alteration is not due to the torsional stress introduced because both supertwisted and relaxed DNA produce the same number of breaks after m-AMSA treatment (unpublished results). Intercalation alone cannot explain the specificity of m-AMSA in stimulating the cleavable complex formation, because both m-AMSA and o-AMSA weakly intercalate into DNA under our assay conditions and the difference in the extent of intercalation is within a factor of 2 (unpublished results). Specific drug-enzyme interaction, in addition to DNA intercalation, must be essential for the antitumor functions of various intercalative drugs. It is possible that drug intercalation may inhibit DNA topoisomerase II independent of its effect on the cleavable complex. It is interesting that oxolinic acid, which can stimulate the cleavage reaction of DNA gyrase and T4 DNA topoisomerase, does not intercalate into DNA. In the case of T4 DNA topoisomerase, cleavage induced by treatment with either oxolinic acid or m-AMSA mapped at the same positions on pBR322 DNA, suggesting a similar mechanism of action that is independent of drug-intercalation into DNA (unpublished results).
Other antitumor drugs such as adriamycin, S-iminodaunorubicin, ellipticine, 2-methyl-9-hydroxyellipticine, and epipodophyllotoxins, VP-16 and VM-26, also stimulate the formation of cleavable complex formation in vitro (unpublished results). Consistent with our proposition that stimulation of the cleavable complex formation is responsible for cytotoxicity, 2-methyl-9-hydroxyellipticine, which is more cytotoxic than ellipticine, is also much more efficient in stimulating the cleavable complex formation in vitro (unpublished results). Stimulation of the cleavable complex formation thus seems to be a general phenomenon for a variety of antitumor drugs. Topoisomerase cleavage sites produced by antitumor drugs from different chemical classes (e.g., anthracyclines, ellipticines, and acridines), however, are quite different. Mammalian DNA topoisomerase II may thus be a multidrug target that responds differently to antitumor drugs from different chemical classes. To test whether mammalian DNA topoisomerase II is the primary cytotoxic target of these antitumor drugs, additional genetic and biochemical studies are neces-Proc. NatL Acad. Sci. USA 81 (1984) 1365 sary. The present correlation studies suggest a possible screening procedure for new antitumor drugs using the in vitro topoisomerase cleavage reaction.
